Letters |

Sedation With Dexmedetomidine vs Lorazepam in Mechanically Ventilated Patients—Reply

Pratik P. Pandharipande, MD, MSCI; Timothy D. Girard, MD, MSCI; E. Wesley Ely, MD, MPH
JAMA. 2008;299(13):1540-1542. doi:10.1001/jama.299.13.1542-a.
Text Size: A A A
Published online


In Reply: Drs Dotson and Peeters and Drs Wunsch and Meltzer correctly note that the pharmacokinetic properties of continuously infused lorazepam could have contributed to oversedation in the control group of our MENDS trial. However, such moderate to heavy use of sedatives continues to characterize usual practice.1,2 When designing and conducting a double-blind trial to evaluate dexmedetomidine, which is only administered via continuous infusion, we chose lorazepam as the control group in accordance with the guidelines of the Society of Critical Care Medicine for long-term sedation of ventilated patients.3 Despite the longer half-life of lorazepam, the majority of patients in both groups were sedated at the level targeted by the ICU team. When undersedation or agitation did occur, study drug boluses were not permitted because of potential adverse effects, but the infusions could be increased and fentanyl boluses were used if pain was suspected. In response to Wunsch and Meltzer, this may have helped preserve blinding, despite the possible inequality of the drug dose titration. A detailed cost-effectiveness analysis is underway, but such an analysis requires the consideration of a number of factors beyond the incidence of delirium or coma, such as organ failure and functional outcomes.


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview




April 2, 2008
Jeffrey F. Barletta, PharmD; John W. Devlin, PharmD
JAMA. 2008;299(13):1540-1542. doi:10.1001/jama.299.13.1541.
April 2, 2008
Hannah Wunsch, MD, MSc; Joseph S. Meltzer, MD
JAMA. 2008;299(13):1540-1542. doi:10.1001/jama.299.13.1540-b.
April 2, 2008
Bryan Dotson, PharmD; Michael J. Peeters, PharmD
JAMA. 2008;299(13):1540-1542. doi:10.1001/jama.299.13.1540-a.
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.